Pivotal Shigella Vaccine Efficacy Trials—Study Design Considerations from a Shigella Vaccine Trial Design Working Group

Vaccine candidates for Shigella are approaching phase 3 clinical trials in the target population of young children living in low- and middle-income countries. Key study design decisions will need to be made to maximize the success of such trials and minimize the time to licensure and implementation....

Descripción completa

Detalles Bibliográficos
Autores principales: Pavlinac, Patricia B., Rogawski McQuade, Elizabeth T., Platts-Mills, James A., Kotloff, Karen L., Deal, Carolyn, Giersing, Birgitte K., Isbrucker, Richard A., Kang, Gagandeep, Ma, Lyou-Fu, MacLennan, Calman A., Patriarca, Peter, Steele, Duncan, Vannice, Kirsten S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032541/
https://www.ncbi.nlm.nih.gov/pubmed/35455238
http://dx.doi.org/10.3390/vaccines10040489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032541/
https://www.ncbi.nlm.nih.gov/pubmed/35455238
http://dx.doi.org/10.3390/vaccines10040489

Ejemplares similares